SAN DIEGO--(BUSINESS WIRE)--Cytori Therapeutics, Inc. (NASDAQ:CYTX) received U.S. Patent No. 7,501,115 (the ‘115 patent), which covers methods of cooling and cryopreserving stem and regenerative cells processed by the Celution® System. This patent provides additional protection for the Company’s cell banking platform, the StemSource® Cell Bank, which Cytori is currently commercializing in both Europe and Asia.
The ‘115 patent protects another specific commercial application of the core Celution® System technology, which is covered under U.S. Patent No. 7,390,484 (the ‘484 patent), issued in July 2008. In addition to the ‘484 patent, the Company now has three patents covering various formulations and applications of the Celution® System output. Collectively, these new patents continue to strengthen Cytori’s proprietary position as it relates to automated systems for processing a heterogeneous mixture of stem and regenerative cells within adipose tissue.
Cytori currently manufactures the Celution® System in the United States to be sold as part of its StemSource® Cell Bank platform to hospitals, tissue banks and stem cell storage organizations in Europe and Asia Pacific. The Celution ®900/MB is an automated system that makes simple and affordable an otherwise cumbersome and costly process of preparing cells for storage. The StemSource® Cell Bank enables organizations to offer their patients’ the opportunity to preserve their own adipose-derived stem and regenerative cells for potential future use as needed.
Cytori’s intellectual property portfolio includes ten issued U.S. and international patents and numerous applications pending worldwide related to the devices, methods and uses of adipose-derived stem and regenerative cells. The Company believes these patents and applications along with its proprietary know-how, exclusive supply agreements, partnerships, and instrumentation create significant market protection for Cytori.
Cytori Therapeutics, Inc. manufactures, develops, and internationally commercializes innovative medical technologies, which allow physicians to practice regenerative medicine. Commercial activities are currently focused on marketing the Celution® cell processing system and related family of products across three areas. The first is cosmetic and reconstructive surgery in Europe and Asia-Pacific. The second is to fulfill the demand among physicians in Europe and Asia Pacific for access to clinical grade stem and regenerative cells. The third is to market the Celution®-based StemSource® Cell Bank worldwide to hospitals and tissue banks so they can in turn offer patients the opportunity to cryopreserve their own adipose-derive stem and regenerative cells. The Company’s development pipeline includes applications for cardiovascular disease, renal failure, orthopedic damage, gastrointestinal disorders, and pelvic health conditions, among others. www.cytoritx.com
Cautionary Statement Regarding Forward-Looking Statements
This press release includes forward-looking statements regarding events, trends and business prospects, which may affect our future operating results and financial position. Such statements are subject to risks and uncertainties that could cause our actual results and financial position to differ materially. Some of these risks and uncertainties include our history of operating losses, the need for further financing, inherent risk and uncertainty in the protection of intellectual property rights, regulatory uncertainties regarding the collection and results of, clinical data, dependence on third party performance, and other risks and uncertainties described under the "Risk Factors" in Cytori's Securities and Exchange Commission Filings, including its annual report on Form 10-K for the year ended December 31, 2008. Cytori assumes no responsibility to update or revise any forward-looking statements contained in this press release to reflect events, trends or circumstances after the date of this press release.